Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
The IBN SINA Pharmaceutical Industry had a gross margin of 39.59% for the quarter that ended in Mar. 2026 => Competition eroding margins
The IBN SINA Pharmaceutical Industry Gross Profit Related Terms
The IBN SINA Pharmaceutical Industry Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The IBN SINA Pharmaceutical Industry Gross Profit Chart
For the Drug Manufacturers - Specialty & Generic subindustry, The IBN SINA Pharmaceutical Industry's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The IBN SINA Pharmaceutical Industry Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The IBN SINA Pharmaceutical Industry's Gross Profit distribution charts can be found below:
* The bar in red indicates where The IBN SINA Pharmaceutical Industry's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5,375 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Gross Profit of BDT5,375 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's Gross Profit too high?
The IBN SINA Pharmaceutical Industry's current Gross Profit is BDT5,375 Mil. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Gross Profit compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's Gross Profit of BDT5,375 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. The IBN SINA Pharmaceutical Industry's current Gross Profit is BDT5,375 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT380.59, compared to a current price of BDT316.70 — trading 16.8% below its estimated fair value. The current Gross Profit is BDT5,375 Mil. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Gross Profit is BDT5,375 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Overvalued in 2026?
Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry stock appears to be undervalued.
The current stock price of BDT316.70 is trading 16.8% below its estimated GF Value™ of BDT380.59.
GuruFocus considers The IBN SINA Pharmaceutical Industry to be Modestly Undervalued.
Key valuation signals for DHA:IBNSINA:
Gross Profit: BDT5,375 Mil
GF Value™: BDT380.59 vs. price of BDT316.70 (16.8% below fair value)
No single metric tells the full story. See the DHA:IBNSINA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score
Get the complete analysis for DHA:IBNSINA
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBNSINA has been successfully added to your 
